Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects

Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorder

(2010) Shoukath M. Ali et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Orally administered Endoxifen is a new therapeutic agent for breast cancer

(2010) Ateeq Ahmad et al.   BREAST CANCER RESEARCH AND TREATMENT

Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients

(2010) Kazuma Kiyotani et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention

(2009) Philip Lazarus et al.   Annals of the New York Academy of Sciences

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor   for Degradation in Breast Cancer Cells

(2009) X. Wu et al.   CANCER RESEARCH

Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment

(2008) Y. Xu et al.   ANNALS OF ONCOLOGY

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

(2008) Kazuma Kiyotani et al.   CANCER SCIENCE